Colorectal Surgery Unit, Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Avenue de La République, Chambray les Tours, France.
EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, Tours, France.
BMC Gastroenterol. 2022 Apr 21;22(1):201. doi: 10.1186/s12876-022-02250-9.
Colorectal cancer is the third most common cancer in France and by the time of the diagnosis, 15-25% of patients will suffer from synchronous liver metastases. Surgery associated to neoadjuvant treatment can cure these patients, but few studies focus only on rectal cancer. This study was meant to compare the outcomes of patients who underwent a simultaneous resection to those who underwent a staged resection (rectum first or liver first) in the University Hospital of Tours, France.
We assessed retrospectively a prospective maintained data base about the clinical, pathological and survival outcomes of patients who underwent a simultaneous or a staged resection in our center between 2010 and 2018. A propensity score matching was used, considering the initial characteristics of our groups.
There were 70 patients (55/15 males, female respectively) with median age 60 (54-68) years. After matching 48 (69%) of them underwent a staged approach and 22 (31%) a simultaneous approach were compared. After PSM, there were 22 patients in each group. No differences were found in terms of morbidity (p = 0.210), overall survival (p = 0.517) and disease-free survival (p = 0.691) at 3 years after matching. There were significantly less recurrences in the simultaneous group (50% vs 81.8%, p = 0.026).
Simultaneous resection of the rectal primary cancer and synchronous liver metastases is safe and feasible with no difference in terms of survival.
结直肠癌是法国第三大常见癌症,在诊断时,15-25%的患者会患有同步肝转移。手术联合新辅助治疗可以治愈这些患者,但很少有研究只关注直肠癌。本研究旨在比较法国图尔大学医院同时行切除术与分期切除术(先直肠或先肝)的患者结局。
我们回顾性评估了一项前瞻性维护的数据库,该数据库记录了 2010 年至 2018 年间在我院接受同时或分期切除术的患者的临床、病理和生存结局。考虑到我们组的初始特征,使用倾向评分匹配。
共 70 例患者(55/15 例男性和女性),中位年龄为 60 岁(54-68 岁)。匹配后,48 例(69%)患者接受分期治疗,22 例(31%)同时治疗的患者进行比较。PSM 后,每组各有 22 例患者。两组之间在发病率(p=0.210)、总生存率(p=0.517)和无病生存率(p=0.691)方面无差异。在匹配后 3 年,同时组的复发率明显较低(50% vs 81.8%,p=0.026)。
直肠原发癌和同步肝转移的同期切除术是安全可行的,在生存率方面无差异。